Drugs / Salidroside
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06990685 | Jun 2025 → Jan 2027 expected | — | The Second Hospital of Shandong University | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Salidroside | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06990685 ↗ |
| Modality | Traditional medicine (herbal / TCM) | “Salidroside is the main active component of Chinese medicine Rhodiola” NCT06990685 ↗ |